

Human Insulin Market to Grow at a CAGR of 8.6% during 2022-2027 | Trends, Size, Share, Report

The global human insulin market reached a value of US\$ 40.4 Billion in 2021.

Looking forward, IMARC Group expects the market to reach US\$ 63.5 Billion by 2027.

UNITED STATES, November 15, 2022 /EINPresswire.com/ -- According to the latest report by IMARC Group "Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", The global [human insulin market size](#) reached US\$ 40.4 Billion in 2021. Looking forward, IMARC Group expects the market to reach US\$ 63.5 Billion by 2027, exhibiting a CAGR of 8.6% during 2022-2027.



Human insulin (HI) is a short-acting insulin that is synthesized in laboratories. Commonly utilized to mimic the function of natural insulin present in humans, it is bio-engineered by growing insulin proteins within E-coli bacteria (*Escherichia coli*). It is available as a solution and suspension and is required to be injected subcutaneously. It is widely employed for controlling the blood sugar levels of patients with type I and II diabetes.

HI functions by aiding the sugar produced by the human body to move from the blood to other body tissues where it is used for energy. It can additionally stop the liver from producing more sugar. Apart from this, HI also assists in inhibiting hepatic glucose production and improving the protein synthesis of the body.

Request for a free sample copy of this report: <https://www.imarcgroup.com/human-insulin-market/requestsampl>

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Human Insulin Market Trends:

The growing prevalence of obesity and diabetes among individuals due to sedentary lifestyles represents one of the key factors driving the market. Apart from this, there is a significant rise in the demand for biosimilar drugs on account of their cost-effectiveness and higher efficiency, which, in turn, is also supporting the growth of the market. Furthermore, the key players are introducing pen devices and safety pen needles for improved delivery of insulin to the body. This, in confluence with the increasing research and development (R&D) activities, is acting as another growth-inducing factor.

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

B. Braun Melsungen AG
Becton Dickinson & Company
Biocon
Eli Lilly and Company
Julphar
Novo Nordisk
Pfizer
Sanofi
Sedico
Wockhardt
Ypsomed Holding, etc.

Explore full report with table of contents: <http://bit.ly/3xiddb4>

The report has segmented the market on the basis of Product Type, End-User and Region.

Breakup by Product Type:

Drugs
Human Insulin Analogs and Biosimilars
Rapid Acting
Long Acting
Premixed
Human Insulin Biologics
Short Acting

Intermediate Acting
Premixed
Delivery Devices
Pens
Reusable Pens
Disposable Pens
Pen Needles
Standard Pen Needles
Safety Pen Needles
Syringes
Others

Breakup by Distribution Channel:

Retail Pharmacies
Hospital Pharmacies
Online Retail Stores
Others

Breakup by Disease Type:

Type I Diabetes
Type II Diabetes

Market Breakup by Region:

North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa

If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Other Trending Reports By IMARC Group

Eye Health Supplements Market: <https://www.digitaljournal.com/pr/eye-health-supplements-market-2022-27-analysis-trends-growth-and-forecast>

Blood Purification Equipment Market: <https://www.digitaljournal.com/pr/blood-purification-equipment-market-share-trends-demand-growth-and-forecast-2022-27>

Cell Isolation Market: <https://www.digitaljournal.com/pr/cell-isolation-market-report-2022-27-growth-share-trends-demand-and-analysis>

Newborn Screening Market: <https://www.digitaljournal.com/pr/newborn-screening-market-size-share-industry-growth-and-forecast-2022-27>

[Pharmacovigilance Market](#)

[Hemophilia Market](#)

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Contact US

IMARC Group

30 N Gould St Ste R

Sheridan, WY 82801 USA - Wyoming

Email: Sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Anand Ranjan

IMARC Services Private Limited

+1 6317911145

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/601345983>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.